{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:50:40Z","timestamp":1793677840680,"version":"4.5.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.antiviral.2020.104751","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T16:37:47Z","timestamp":1582216667000},"page":"104751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy"],"prefix":"10.1016","volume":"176","author":[{"given":"Edin J.","family":"Mifsud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Tilmanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding Yuan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Ming-Kay Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron C.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104751_bib1","doi-asserted-by":"crossref","first-page":"15731","DOI":"10.1074\/jbc.M117.791863","article-title":"The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice","volume":"292","author":"Amireddy","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104751_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(17)30476-0","article-title":"Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Beigel","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104751_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.03947-14","article-title":"Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro","volume":"59","author":"Belardo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104751_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104751_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2018.01.009","article-title":"Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle","volume":"151","author":"Criscuolo","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104751_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104751_bib7","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.antiviral.2020.104751_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/ca448e7c-fbbc-43e9-9981-108c9bfa8bce","article-title":"Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial","volume":"7","author":"Duval","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104751_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.antiviral.2012.08.002","article-title":"Oseltamivir\u2013zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections","volume":"96","author":"Escuret","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104751_bib10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3390\/v2081510","article-title":"Combination chemotherapy for influenza","volume":"2","author":"Govorkova","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2020.104751_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2334-6-58","article-title":"Occurrence of invasive pneumococcal disease and number of excess cases due to influenza","volume":"6","author":"Grabowska","year":"2006","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104751_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.280.1.35","article-title":"Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for hiv-1 infection: 100-week follow-up","volume":"280","author":"Gulick","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2020.104751_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104751_bib14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2147\/TCRM.S87789","article-title":"Virus-induced secondary bacterial infection: a concise review","volume":"11","author":"Hendaus","year":"2015","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.antiviral.2020.104751_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029778","article-title":"Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus","volume":"6","author":"Hoopes","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104751_bib16","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1128\/JVI.00373-10","article-title":"Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model","volume":"84","author":"Hurt","year":"2010","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2020.104751_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001269.pub4","article-title":"Vaccines for preventing influenza in healthy adults","author":"Jefferson","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2020.104751_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/ja963036t","article-title":"Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active Site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity","volume":"119","author":"Kim","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.antiviral.2020.104751_bib19","doi-asserted-by":"crossref","first-page":"C9","DOI":"10.1016\/j.vaccine.2009.06.007","article-title":"Pneumococcal pneumonia and influenza: a deadly combination","volume":"27","author":"Klugman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2020.104751_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/1476-072X-11-16","article-title":"Annual economic impacts of seasonal influenza on US counties: spatial heterogeneity and patterns","volume":"11","author":"Mao","year":"2012","journal-title":"Int. J. Health Geogr."},{"key":"10.1016\/j.antiviral.2020.104751_bib21","doi-asserted-by":"crossref","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice","volume":"6","author":"Marathe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2020.104751_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094090","article-title":"Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir","volume":"9","author":"Marriott","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104751_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/jcm.13.1.54-57.1981","article-title":"Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test","volume":"13","author":"Monto","year":"1981","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104751_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.antiviral.2020.104751_bib25","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1128\/AAC.00476-09","article-title":"Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104751_bib26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJMoa070844","article-title":"Effectiveness of influenza vaccine in the community-dwelling elderly","volume":"357","author":"Nichol","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104751_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118780","article-title":"A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity","volume":"10","author":"Oh","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104751_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmicb.2016.00080","article-title":"Using the ferret as an animal model for investigating influenza antiviral effectiveness","volume":"7","author":"Oh","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104751_bib29","article-title":"Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice","volume":"9","author":"Park","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104751_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1468-1293.2002.00109.x","article-title":"Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy","volume":"3","author":"Raboud","year":"2002","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2020.104751_bib31","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2020.104751_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104751_bib33","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104751_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2475","article-title":"Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics","volume":"18","author":"Seo","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104751_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2010.07.003","article-title":"Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice","volume":"88","author":"Smee","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104751_bib36","first-page":"349","article-title":"Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers","volume":"34","author":"Stockis","year":"1996","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.antiviral.2020.104751_bib37","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.43.17-00707","article-title":"Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017","volume":"22","author":"Sullivan","year":"2017","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2020.104751_bib38","article-title":"Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations","volume":"7","author":"Sullivan","year":"2019","journal-title":"Ther. Adv. Vaccine. Immunother"},{"key":"10.1016\/j.antiviral.2020.104751_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1750-2659.2009.00073.x","article-title":"Estimates of US influenza-associated deaths made using four different methods","volume":"3","author":"Thompson","year":"2009","journal-title":"Influenza. Respir. Viruses"},{"key":"10.1016\/j.antiviral.2020.104751_bib40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104751_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2020.104751_bib42","series-title":"Influenza (Seasonal), Fact Sheet","author":"WHO","year":"2018"},{"key":"10.1016\/j.antiviral.2020.104751_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12879-016-1383-8","article-title":"Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219306138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219306138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:31:25Z","timestamp":1759062685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219306138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":43,"alternative-id":["S0166354219306138"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104751","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104751"}}